home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9406d.zip
/
M9460713.TXT
< prev
next >
Wrap
Text File
|
1994-06-25
|
2KB
|
40 lines
Document 0713
DOCN M9460713
TI Treatment research priorities for human immunodeficiency virus
infection.
DT 9408
AU Pettinelli CB; Schnittman SM; Division of AIDS, National Institute of
Allergy and Infectious; Disease, National Institutes of Health,
Rockville, Maryland.
SO Infect Agents Dis. 1993 Oct;2(5):291-303. Unique Identifier : AIDSLINE
MED/94228152
AB Viral infections such as with the human immunodeficiency virus (HIV)
present difficult challenges for the development of effective antiviral
therapies. These viruses depend on the host cell machinery for their
existence, and interference with these processes typically interferes
with other important host physiology. HIV presents other challenges as
well because of its inherent pathogenic destruction of the immune
system. It is the goal of HIV therapeutics to attempt to cure HIV
infection, or if that is not possible, to stop HIV disease progression
while preserving a high quality of life for HIV-infected individuals.
This may be achieved through an effective combination of interference
with the viral life cycle and the pathogenic processes, and by slowing
or reversing the immunologic dysfunction that leads to the complications
of HIV infection. Unprecedented progress has been made in understanding
the virus and HIV disease pathogenesis. This knowledge has led to the
identification of viral features that have become targets for
therapeutic intervention. This article reviews the most important
priorities of HIV treatment research for adult HIV-infected patients for
the immediate future. These priorities include the following:
development of new antiretroviral compounds and their application as
both monotherapies and in combination therapy approaches; immune-based
therapeutic approaches; and research and treatment for acute or primary
HIV infections.
DE Antiviral Agents/THERAPEUTIC USE Drug Therapy, Combination Human HIV
Infections/*THERAPY HIV-1 Immunotherapy JOURNAL ARTICLE REVIEW
REVIEW, ACADEMIC
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).